IKT · Inhibikase Therapeutics, Inc. · Earnings Calls, Transcripts & Webcasts
$1.32
+0.02 (+1.54%)
At close · Nov 20
Return incl. dividend (before tax)
Q2 2024 earnings call transcript
Market Cap
$185.16M
Shares
140.27M
Volume · Nov 20
1.11M
Avg daily vol (3M)
580.26K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Inhibikase Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Inhibikase Therapeutics, Inc. (IKT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-12-02
Inhibikase Therapeutics, Inc. (IKT) December 2, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-16
Inhibikase Therapeutics, Inc. (IKT) November 16, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-10
Inhibikase Therapeutics, Inc. (IKT) Q3 2026 Earnings Call
Net interest income
$1.76M
▲ 110.2% YoY Diluted EPS
$-0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-08-11
Inhibikase Therapeutics, Inc. (IKT) Q2 2026 Earnings Call
Revenue
$0
Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Inhibikase Therapeutics, Inc. (IKT) Q1 2026 Earnings Call
Revenue
$0
Diluted EPS
$-0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-26
Inhibikase Therapeutics, Inc. (IKT) Q4 2025 Earnings Call
Net interest income
$1.04M*
▲ 30.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-14
Inhibikase Therapeutics, Inc. (IKT) Q3 2025 Earnings Call
Revenue
$0
Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Inhibikase Therapeutics, Inc. (IKT) Q2 2025 Earnings Call
Revenue
$0
Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
Inhibikase Therapeutics, Inc. (IKT) Q1 2025 Earnings Call
Revenue
$0
Diluted EPS
$-0.15
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
Inhibikase Therapeutics, Inc. (IKT) Q4 2024 Earnings Call
Revenue
$0*
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q2
2024-06-30
Date not confirmed
Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript
Positive tone
IkT-001Pro in pulmonary arterial hypertension
Cash position and capital needs
Biomarker and diagnostic tools
Revenue
$0
▼ 100% YoY Diluted EPS
$-0.66
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Date not confirmed
Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call Transcript
Confident tone
Pulmonary Arterial Hypertension (PAH) Opportunity
Alpha-Synuclein Biomarker and Antibody Development
Capital Needs and Financing Constraints
Revenue
$0
▼ 100% YoY Diluted EPS
$-0.73
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Date not confirmed
Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript
Revenue
$1*
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Date not confirmed
Inhibikase Therapeutics, Inc. (IKT) Q3 2023 Earnings Call Transcript
Revenue
$79,569
▲ 991.3% YoY Diluted EPS
$-0.86
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Date not confirmed
Inhibikase Therapeutics, Inc. (IKT) Q2 2023 Earnings Call Transcript
Revenue
$116,410
▲ 1676.7% YoY Diluted EPS
$-1.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Date not confirmed
Inhibikase Therapeutics, Inc. (IKT) Q1 2023 Earnings Call Transcript
Revenue
$64,521
▲ 40.2% YoY Diluted EPS
$-0.98
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Date not confirmed
Inhibikase Therapeutics, Inc. (IKT) Q4 2022 Earnings Call Transcript
Revenue
$63,566*
▲ 3169.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-17
Inhibikase Therapeutics, Inc. (IKT) Q3 2022 Earnings Call Transcript
Revenue
$7,291
▼ 97.8% YoY Diluted EPS
$-1.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Date not confirmed
Inhibikase Therapeutics, Inc. (IKT) Q2 2022 Earnings Call Transcript
Revenue
$6,552
▼ 99.5% YoY Diluted EPS
$-1.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Date not confirmed
Inhibikase Therapeutics, Inc. (IKT) Q1 2022 Earnings Call Transcript
Revenue
$46,031
▼ 96.7% YoY Diluted EPS
$-1.08
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Date not confirmed
Inhibikase Therapeutics, Inc. (IKT) Q4 2021 Earnings Call Transcript
Revenue
$1,944*
▼ 98.9% YoY
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q4
2021-04-01
Inhibikase Therapeutics, Inc. (IKT) Q4 2020 Earnings Call
Revenue
$170,416*
Rev · 3q
Audio
Transcript
Slides
8-K10-K
Showing 1–22 of 22 webcasts
Key facts
CIK
1750149
CUSIP
45719W205
13F (30d)
109 filings
103 filers
Visit website
Investor relations